Skip to content
Medical Health Aged Care

Fish oil supplement halves serious cardiovascular events in patients on dialysis

Monash University 2 mins read

A daily fish oil supplement has been shown to significantly reduce serious cardiovascular events in people receiving dialysis for kidney failure. The findings come from a major international clinical trial co-led in Australia by Monash Health and the School of Clinical Sciences at Monash University.

The PISCES trial involved 1,228 participants across 26 dialysis sites in Australia and Canada. Results were presented at the American Society of Nephrology Kidney Week 2025 and published simultaneously in The New England Journal of Medicine.

Participants who received four grams per day of fish oil, containing the natural active ingredients EPA and DHA, experienced a 43 per cent lower rate of serious cardiovascular events compared with the placebo group. These events included heart attack, stroke, cardiac death and vascular related amputations. 

Adjunct Professor Kevan Polkinghorne, nephrologist at Monash Health and adjunct in the School of Clinical Sciences, served as the lead investigator for the Australian arm.

“Patients on dialysis have extremely high cardiovascular risk, and very few therapies have been shown to reduce that risk,” Professor Polkinghorne said. “In a field where many trials have been negative, this is a significant finding.

“Dialysis patients typically have much lower levels of EPA and DHA than the general population. This may help explain the magnitude of benefit observed in this group.”

Professor Polkinghorne noted that the findings are specific to people receiving haemodialysis for kidney failure and should not be applied to healthy individuals or other patient groups. 

The Australian arm was supported by the National Health and Medical Research Council (NHMRC). Central trial coordination was provided by the Australasian Kidney Trials Network (AKTN). Around 200 Australian participants contributed to the study, including 44 treated at Monash Health.

International leadership for PISCES was provided by Professor Charmaine Lok and colleagues at the University Health Network in Toronto and the University of Calgary.

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site 

More from this category

  • Government VIC, Medical Health Aged Care
  • 08/12/2025
  • 07:53
Public Health Association of Australia

Five VicHealth former chairs urge government retain the health promotion foundation

Open letter to the Victorian Premier, Treasurer, and Health Minister (Issued by the Public Health Association of Australia on the authors' behalf). 8 December 2025 As five former Chairs ofVicHealth, representing a broad political spectrum and different eras of VicHealth’s work, we write to ask you to reconsider your Government’s decision to abolish VicHealth and place its important preventative health functions in the Health Department.We believe the decision is misguided and will fail to deliver the hoped-for savings. Abolishing VicHealth will severely reduce the effectiveness of important and innovative public health work in this State. Even with the best intentions,…

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.